Promoter methylation of DAL-1/4.1B predicts poor prognosis in non-small cell lung cancer

Clinical Cancer Research

Volumn 11, Issue 8, 2005, Pages 2954-2961

  Kikuchi, Shinji ^a   Yamada, Daisuke ^a   Fukami, Takeshi ^a   Masuda, Mari ^a   Sakurai Yageta, Mika ^a   Williams, Yuko N ^a   Maruyama, Tomoko ^a   Asamura, Hisao ^b   Matsuno, Yoshihiro ^b   Onizuka, Masataka ^c   Murakami, Yoshinori ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

^c UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ACTIN BINDING PROTEIN; BISULFITE; DAL 1 PROTEIN; MICROSATELLITE DNA; UNCLASSIFIED DRUG;

ALLELE; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CHROMOSOME 18P; CONTROLLED STUDY; CORRELATION ANALYSIS; DEMETHYLATION; DNA METHYLATION; GENE EXPRESSION; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE STRAND CONFORMATION POLYMORPHISM; SQUAMOUS CELL CARCINOMA; SURVIVAL TIME;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CHROMOSOMES, HUMAN, PAIR 18; CPG ISLANDS; DNA METHYLATION; DNA, NEOPLASM; HUMANS; LOSS OF HETEROZYGOSITY; LUNG NEOPLASMS; MEMBRANE PROTEINS; MITOTIC INDEX; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROGNOSIS; PROMOTER REGIONS (GENETICS); SEQUENCE ANALYSIS, DNA; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEINS;

EID: 20244390458     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-2206     Document Type: Article

References (25)

1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin 2004;54:8-29.
2. Fong KM, Sekido Y, Gazdar AF, Minna JD. Lung cancer. 9: Molecular biology of lung cancer: clinical implications. Thorax 2003;58:892-900.
3. Merlo A, Herman JG, Mao L, et al. 5′ CpG island methylation is associated with transcriptional silencing of the tumor suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1995;1:686-92.
4. Dammann R, Li C, Yoon JH, Chin PL, Bates S, Pfeifer GP. Epigenetic inactivation of a RAS association domain family protein from the lung tumor suppressor locus 3p21.3. Nat Genet 2000;25:315-9.
5. Murakami Y, Nobukuni T, Tamura K, et al. Localization of tumor suppressor activity important in non-small cell lung carcinoma on chromosome 11q. Proc Natl Acad Sci U S A 1998;95:8153-8.
6. Kuramochi M, Fukuhara H, Nobukuni T, et al. TSLC1 is a tumor-suppressor gene in human non-small cell lung cancer. Nat Genet 2001;27:427-30.
7. Gomyo H, Arai Y, Tanigami A, et al. A2-Mb sequence-ready contig map and a novel immunoglobulin superfamily gene IGSF4 in the LOH region of chromosome 11q23.2. Genomics 1999;62:139-46.
8. Masuda M, Yageta M, Fukuhara H, et al. The tumor suppressor protein TSLC1 is involved in cell-cell adhesion. J Biol Chem 2002;277:31014-9.
9. Fukami T, Fukuhara H, Kuramochi M, et al. Promoter methylation of the TSLC1 gene in advanced lung tumors and various cancer cell lines. Int J Cancer 2003;107:53-9.
10. Yageta M, Kuramochi M, Masuda M, et al. Direct association of TSLC1 and DAL-1, two distinct tumor suppressor proteins, in lung cancer. Cancer Res 2002;62:5129-33.
11. Tran YK, Bogler O, Gorse KM, Wieland I, Green MR, Newsham IF. A novel member of the NF2/ERM/4.1 superfamily with growth suppressing properties in lung cancer. Cancer Res 1999;59:35-43.
12. Gutmann DH, Hirbe AC, Huang ZY, Haipek CA. The protein 4.1 tumor suppressor, DAL-1, impairs cell motility, but regulates proliferation in a cell-type-specific fashion. Neurobiol Dis 2001;8:266-78.
13. Charboneau AL, Singh V, Yu T, Newsham IF. Suppression of growth and increased cellular attachment after expression of DAL-1 in MCF-7 breast cancer cells. Int J Cancer 2002;100:181-8.
14. Frommer M, McDonald LE, Millar DS, et al. A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc Natl Acad Sci U S A 1992;89:1827-31.
15. Veigl ML, Kasturi L, Olechnowicz J, et al. Biallelic inactivation of hMLH1 by epigenetic gene silencing, a novel mechanism causing human MSI cancers. Proc Natl Acad Sci U S A 1998;95:8698-702.
16. Antequera F, Bird A. Number of CpG islands and genes in human and mouse. Proc Natl Acad Sci U S A 1993;90:11995-9.
17. Gutmann DH, Donahue J, Perry A, et al. Loss of DAL-1, a protein 4.1-related tumor suppressor, is an important early event in the pathogenesis of meningiomas. Hum Mol Genet 2000;9:1495-500.
18. Tran Y, Benbatoul K, Gorse K, et al. Novel regions of allelic deletion on chromosome 18p in tumors of the lung, brain, and breast. Oncogene 1998;17:3499-505.
19. Kittiniyom K, Gorse KM, Dalbegue F, Lichy JH, Taubenberger JK, Newsham IF. Allelic loss on chromosome band 18p11.3 occurs early and reveals heterogeneity in breast cancer progression. Breast Cancer Res 2001;3:192-8.
20. Kittiniyom K, Mastronardi M, Roemer M, et al. Allele-specific loss of heterozygosity at the DAL-1/ 4.1B (EPB41L3) tumor-suppressor gene locus in the absence of mutation. Genes Chromosomes Cancer 2004;40:190-203.
21. Hiyoshi H, Matsuno Y, Kato H, Shimosato Y, Hirohashi S. Clinicopathological significance of nuclear accumulation of tumor suppressor gene p53 product in primary lung cancer. Jpn J Cancer Res 1992;83:101-6.
22. Yu T, Robb VA, Singh V, Gutmann DH, Newsham IF. The 4.1/ezrin/radixin/ moesin domain of the DAL-1/ Protein 4.1B tumor suppressor interacts with 14-3-3 proteins. Biochem J 2002;365:783-9.
23. Robb VA, Li W, Gutmann DH. Disruption of 14-3-3 binding does not impair protein 4.1B growth suppression. Oncogene 2004;23:3589-96.
24. Allinen M, Peri L, Kujala S, et al. Analysis of 11q21-24 loss of heterozygosity candidate target genes in breast cancer: indications of TSLC1 promoter hypermethylation. Genes Chromosomes Cancer 2002;34:384-9.
25. Surace EI, Murakami Y, Scheithauer BW, Perry A, Gutmann DH. Tumor suppressor in lung cancer-1 (TSLC1) expression is lost in sporadic meningioma. J Neuropathol Exp Neurol 2004;63:1015-27.